Tenofovir
- Generic Name
- Tenofovir
- Brand Names
- Vemlidy, Tenofovir disoproxil Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H14N5O4P
- CAS Number
- 147127-20-6
- Unique Ingredient Identifier
- W4HFE001U5
- Background
Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in ...
- Indication
Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.
To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, tenofovir alafenamide and tenofovir disoproxil.
- Associated Conditions
- -
- Associated Therapies
- -
Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00409019
Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients
- Conditions
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2009-10-20
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 30
- Registration Number
- NCT00358696
- Locations
- π¨π¦
Pender Community Health Centre, Vancouver, British Columbia, Canada
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
- Conditions
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT00350272
- Locations
- π΅π·
Clinical Trial Site, San Juan, Puerto Rico
Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression
- Conditions
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 9
- Registration Number
- NCT00344981
- Locations
- πΊπΈ
University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States
Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 21
- Registration Number
- NCT00214890
- Locations
- πΊπΈ
University of California San Diego, San Diego, California, United States
πΊπΈHarbor-UCLA Medical Center, Torrance, California, United States
πΊπΈUCI, Irvine, California, United States
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00192660
- Locations
- π¦πΊ
St. Vincent's Hospital, Sydney, New South Wales, Australia
Tenofovir in HIV/HBV Coinfection
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00192595
- Locations
- π¦πΊ
St. Vincent's Hospital, Darlinghurst, New South Wales, Australia
πΉπThai Red Cross AIDS Research Centre, Bangkok, Thailand
π¦πΊThe Alfred Hospital, Melbourne, Victoria, Australia
Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection
- Conditions
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2007-04-24
- Target Recruit Count
- 24
- Registration Number
- NCT00127959
- Locations
- π³π±
Academic Medical Center, Amsterdam, NH, Netherlands
Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients
- Conditions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2005-07-28
- Target Recruit Count
- 50
- Registration Number
- NCT00122577
- Locations
- π«π·
Service d'Immunologie clinique Hopital Europeen Georges Pompidou, Paris, France
A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
- Conditions
- First Posted Date
- 2003-02-05
- Last Posted Date
- 2010-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 345
- Registration Number
- NCT00053638
- Locations
- πΊπΈ
GSK Investigational Site, Green Bay, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.